Blueprint Medicines Newsroom

Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)

TipRanksAug 7 14:06

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

BenzingaAug 6 03:14

Blueprint Medicines Analyst Ratings

BenzingaAug 6 03:13

TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating

Futu NewsAug 5 19:33

Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Raises Target Price to $105

Futu NewsAug 5 16:32

Blueprint Medicines (BPMC) Receives a Hold From Barclays

TipRanksAug 5 15:54

Blueprint Medicines Price Target Raised to $138.00/Share From $130.00 by Guggenheim

Dow JonesAug 3 03:20

Blueprint Medicines Analyst Ratings

BenzingaAug 2 23:27

Baird Maintains Outperform on Blueprint Medicines, Raises Price Target to $127

BenzingaAug 2 22:45

A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $120 to $135

Futu NewsAug 2 21:02

Needham Reiterates Buy on Blueprint Medicines, Maintains $130 Price Target

BenzingaAug 1 20:47

Blueprint Medicines Analyst Ratings

BenzingaAug 1 20:45

Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $130

Futu NewsAug 1 20:32

Buy Rating Affirmed: Blueprint Medicines Surpasses Q2 Revenue Estimates With Ayvakit's Success

TipRanksAug 1 20:04

Blueprint Medicines Analyst Ratings

BenzingaJul 29 23:45

Barclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)

TipRanksJul 29 16:17

Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)

TipRanksJul 23 18:45

Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)

TipRanksJul 19 20:18

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

BenzingaJul 13 01:19

Blueprint Medicines Analyst Ratings

BenzingaJul 13 01:18